Tags

Type your tag names separated by a space and hit enter

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy.
Vaccine 2003; 21(25-26):3629-37V

Abstract

OBJECTIVE

To study immunological and virological parameters in HIV-1-seropositive adults treated with highly active antiretroviral therapy (HAART) for at least 7 months after immunisation with MF59-adjuvanted (FLUAD, Chiron, Siena, Italy) or with non-adjuvanted (AGRIPPAL, Chiron) trivalent influenza vaccine.

DESIGN

Blood samples, collected before and after vaccination, were analysed for the presence of antibodies against the vaccine antigens, for number of CD4+ T lymphocytes and HIV-1 RNA levels.

RESULTS

Forty-four volunteers received FLUAD and 40 AGRIPPAL influenza vaccine. Thirty days after vaccination both adjuvanted and non-adjuvanted vaccines induced significant increases of anti-influenza virus antibodies. However, antibody titres found in volunteers receiving adjuvanted vaccine were in general significantly higher when compared with those found in the non-adjuvanted vaccine group. The requirements of the European Commission of influenza vaccine for a non-elderly adult population were always met by recipients of the adjuvanted vaccine, even in those with the lowest CD4+ cell counts (<200 cells/mmc). The subjects receiving the non-adjuvanted vaccine failed to met these requirements. The CD4+ T lymphocytes and plasma HIV-1 RNA levels remained stable in the long term, both in people receiving adjuvanted or non-adjuvanted vaccine.

CONCLUSION

MF59-adjuvanted influenza induced a significant higher immune responses as compared with conventional vaccine in HIV-seropositive HAART-treated patients. Both vaccines were safe regarding HIV RNA viral replication and loss of CD4+ T lymphocytes.

Authors+Show Affiliations

Department of Hygiene, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. anna@unipg.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12922092

Citation

Iorio, Anna M., et al. "Antibody Responses and HIV-1 Viral Load in HIV-1-seropositive Subjects Immunised With Either the MF59-adjuvanted Influenza Vaccine or a Conventional Non-adjuvanted Subunit Vaccine During Highly Active Antiretroviral Therapy." Vaccine, vol. 21, no. 25-26, 2003, pp. 3629-37.
Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine. 2003;21(25-26):3629-37.
Iorio, A. M., Francisci, D., Camilloni, B., Stagni, G., De Martino, M., Toneatto, D., ... Podda, A. (2003). Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine, 21(25-26), pp. 3629-37.
Iorio AM, et al. Antibody Responses and HIV-1 Viral Load in HIV-1-seropositive Subjects Immunised With Either the MF59-adjuvanted Influenza Vaccine or a Conventional Non-adjuvanted Subunit Vaccine During Highly Active Antiretroviral Therapy. Vaccine. 2003 Sep 8;21(25-26):3629-37. PubMed PMID: 12922092.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. AU - Iorio,Anna M, AU - Francisci,Daniela, AU - Camilloni,Barbara, AU - Stagni,Giuliano, AU - De Martino,Matteo, AU - Toneatto,Daniela, AU - Bugarini,Roberto, AU - Neri,Mariella, AU - Podda,Audino, PY - 2003/8/19/pubmed PY - 2004/3/26/medline PY - 2003/8/19/entrez SP - 3629 EP - 37 JF - Vaccine JO - Vaccine VL - 21 IS - 25-26 N2 - OBJECTIVE: To study immunological and virological parameters in HIV-1-seropositive adults treated with highly active antiretroviral therapy (HAART) for at least 7 months after immunisation with MF59-adjuvanted (FLUAD, Chiron, Siena, Italy) or with non-adjuvanted (AGRIPPAL, Chiron) trivalent influenza vaccine. DESIGN: Blood samples, collected before and after vaccination, were analysed for the presence of antibodies against the vaccine antigens, for number of CD4+ T lymphocytes and HIV-1 RNA levels. RESULTS: Forty-four volunteers received FLUAD and 40 AGRIPPAL influenza vaccine. Thirty days after vaccination both adjuvanted and non-adjuvanted vaccines induced significant increases of anti-influenza virus antibodies. However, antibody titres found in volunteers receiving adjuvanted vaccine were in general significantly higher when compared with those found in the non-adjuvanted vaccine group. The requirements of the European Commission of influenza vaccine for a non-elderly adult population were always met by recipients of the adjuvanted vaccine, even in those with the lowest CD4+ cell counts (<200 cells/mmc). The subjects receiving the non-adjuvanted vaccine failed to met these requirements. The CD4+ T lymphocytes and plasma HIV-1 RNA levels remained stable in the long term, both in people receiving adjuvanted or non-adjuvanted vaccine. CONCLUSION: MF59-adjuvanted influenza induced a significant higher immune responses as compared with conventional vaccine in HIV-seropositive HAART-treated patients. Both vaccines were safe regarding HIV RNA viral replication and loss of CD4+ T lymphocytes. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/12922092/Antibody_responses_and_HIV_1_viral_load_in_HIV_1_seropositive_subjects_immunised_with_either_the_MF59_adjuvanted_influenza_vaccine_or_a_conventional_non_adjuvanted_subunit_vaccine_during_highly_active_antiretroviral_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264410X03004080 DB - PRIME DP - Unbound Medicine ER -